期刊文献+

巯基嘌呤甲基转移酶基因突变与儿童急性淋巴细胞白血病治疗不良反应的关系 被引量:9

The effect of the adverse events with thiopurine S-methyltransferase gene mutation on outcome of childhood acute lymphoblastic leukemia
原文传递
导出
摘要 目的探讨巯基嘌呤甲基转移酶(TPMT)活性和其遗传多态性在儿童急性淋巴细胞白血病(ALL)个体化治疗中的临床意义。方法运用高效液相色谱法(HPLC)对100例初诊ALL患儿、180名健康儿童进行TPMT活性检测。采用在线Primer3软件设计引物,对30例具有临床事件的患儿进行TPMT基因DNA测序。分析TPMT活性、遗传多态性与临床不良反应的相关性。TPMT活性以在单位时间(1h)内单位质量的血红蛋白(Hb,g)催化生成的2-氨基-6-甲基巯基嘌呤(6-MTG)的量(nm01)表示。结果100例初诊ALL患儿TPMT活性为(31.72±10.31)nmol·g^-1Hb·h^-1,180名健康儿童TPMT活性为(30.70±9.67)nmol·g^-1Hb·h^-1,两者TPMT活性差异无统计学意义(P=0.450)。19例发生严重骨髓抑制的患儿TPMT活性为(20.96±7.24)nmol·g^-1Hb·h^-1,6例ALL复发者初诊时TPMT活性为(40.46±8.18)nmol·g^-1Hb·h^-1,两者分别与30例具有临床事件的ALL患儿初诊时活性[(24.07±11.43)nmol·g^-1Hb·h^-1]相比差异具有统计学意义(P值均〈0.05)。5例化疗后发生严重肝脏毒性者初诊时TPMT活性为(23.60±7.48)nmol·g^-1Hb·h^-1,与30例ALL患儿初诊时活性相比差异无统计学意义(P=0.930)。对30例具有临床事件的ALL患儿TPMT基因DNA测序,3例发生TPMTS3C杂合突变,其活性为(11.99±1.32)nmol·g^-1Hb·h^-1,27例呈野生纯合型,其活性为(24.95±11.32)nmol·g^-1Hb·h^-1,杂合子突变患儿TPMT活性明显低于野生纯合子型患儿,差异有统计学意义(P〈0.05)。启动子-100附近区域发现5种数El变异的串联重复(VNTR)基因型(*V3/*V3、*V3/*V4、*V4/*V4、*V5/*V5、*V4/*V6),其平均活性分别为19.35、25.06、22.61、32.16、11.85nmol·g^-1Hb·h^-1,各组间活性差异无统计学意义(P=0.186)。结论TPMT基因多态性与其活性有一定的相关性,TPMT活性高低对于儿童ALL预后的判断和指导个体化用药有重要的临床意义。 Objective To investigate thiopurine S-methyltransferase (TPMT) activity and gene pro- moter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children. Methods The average TPMT activities were (31.72 ± 10.31) nmol·g-1Hb·h-1 and ( 30.70 ± 9.67 ) nmol ·g-1Hb·h-1 in ALL and healthy groups respectively, without gender differences of TPMT activities ( P = 0.45 ) in both groups. The TPMT activity with clinical events in newly diagnosed ALL patients ( n = 30) was (24.07 ± 11.43 ) nmol ·g - 1Hb · h - 1. There are significant differences of TPMT activities between severe bone marrow suppression [ ( 20.96 ± 7.24) nmol · g-1 Hb·h - 1 ] and ALL patients with clinical events groups (P 〈 0.05 ). The TPMT activity of(40.46± 8.18) nmol · g-XHb·h-1 in recur- rence children was also significantly different ( P 〈 0.05 ). TPMT activity in severe liver toxicity group was not significantly different (P = 0. 930 ). Of TPMT gene sequencing in ALL patients with clinical events,only 3 children were heterozygosity mutations of TPMT * 3C, while others homozygous genotype. There were significant differences of TPMT activities between heterozygosity genotype [ ( 11.99 ± 1.32) nmol · g-1 Hb · h-1] and homozygous genotype groups [ (24.95 ± 11.32) nmol·g-1Hb·h-1 ] (P 〈0.05). There were five kinds of variations at the vicinity of the promoter region of - 100 of tandem repeats (VNTR) polymor- phism( * V3/* V3, * V3/* V4, * V4/* V4, * V5/* V5, * V4/* V6 ) without significant differences of TPMT activities among five kinds (P = 0.186). Conclusion TPMT activity was related to the gene polymorphism. TPMT activity determination had prognostic value and guided individualized treatment.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2013年第3期247-252,共6页 Chinese Journal of Hematology
基金 国家“十一五”科技支撑计划项目(2007BA104803)
关键词 白血病 淋巴细胞 急性 巯嘌呤甲基转移酶 多态性 单核苷酸 DNA突变分析 硫鸟嘌呤核苷酸 Acute lymphoblastic leukemia Thiopurine S-methyhransferase Polymorphism Gene mutation Thioguanine nucieotides
  • 相关文献

参考文献14

  • 1Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther, 2006,23 : 11-25.
  • 2Wang L, Sullivan W, Toft D, et al. Thiopurine S-methyltransferase pharmacogenetics:chaperone protein association and allozyme deg- radation. Pharmcogenetics, 2003,13:555-564.
  • 3Wang L, Nguyen TV, McLaughlin RW, et al. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A, 2005,102: 9394-9399.
  • 4Salavaggione OE,Wang L,Wiepert M, et al. Thiopurine S-methyl- transferase pharmacogenetics:variant allele functional and compar- ative genomics. Pharmacogenet Genomics ,2005,15 : 801-815.
  • 5Lindqvist M, Haglund S, Almer S, et al. Identification of two novel seduence variants affecting thiopurine S-methyltransferase enzyme activity. Pharmacogenetics,2004,14:261-265.
  • 6Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltrans- ferase (TPMT) genotype and early treatment response to mercapto- purine in childhood acute lymphoblastic leukemia. JAMA, 2005, 293:1485-1489.
  • 7马晓莉,朱平,吴敏媛,李志刚,胡亚美.巯嘌呤甲基转移酶基因多态性位点与白血病巯嘌呤耐受性的关系[J].中华儿科杂志,2003,41(12):929-933. 被引量:11
  • 8张建萍,关永源,吴珏珩,姜文奇,黄民.健康汉族人硫嘌呤甲基转移酶遗传多态性研究[J].癌症,2003,22(4):385-388. 被引量:21
  • 9Kham SK, Soh CK, Liu TC, et al. Thiopurine S-methyhransferase activity in three major Asian populations:a population-based study in Singapore. Eur J Clin Pharmaco1,2008 ,64 :373-379.
  • 10Hard DL, Jones EW. DNA structure and DNA Manipulation// Hard DL,Jones EW. Genetics: analysis of Genes and Genomes. 15th ed. UK,.lones and Battled Puhlishier 2001 .66-73.

二级参考文献13

  • 1Lennard L, Singleton HJ. High-performance liquid chromatographic assay of human red blood cell thiopurine methyhransferase activity. J Chromatogr B Biomed Appl, 1994, 661 : 25-33.
  • 2Ganiere-Monteil C, Pineau A, Kergueris MF, et al. Thiopurine methyl transferase activity: new extraction conditions for high-pedormance liquid chromatographic assay. J Chromatogr B Biomed Sci Appl, 1999, 727: 235-239.
  • 3Coulthard SA, Matheson EC, Hall AG, et al. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.Nucleosides Nucleotides Nucleic Acids, 2004, 23:1385-1391.
  • 4Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer, 1998, 34 : 1493-1499.
  • 5Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastie leukemia. JAMA,2005, 293 : 1485-1489.
  • 6MeLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol, 1999, 105:696-700.
  • 7Weinshilboum R. Thiopurine pharmacogeneties : clinical and molecular studies of thiopurine methyhransferase. Drug Metab Dispos, 2001, 29:601-605.
  • 8Keuzenkamp-Jansen CW, Leegwater PA, De Abreu RA, et al.Thiopurine methyltransferase: a review and a clinical pilot study. J Chromatogr B Biomed Appl, 1996, 678 : 15-22.
  • 9McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther, 1994, 55 : 15-20.
  • 10Capdeville R, Mousson B, Bax G, et al. Interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT)activity. Eur J Clin Pharmacol, 1994, 46 : 385-386.

共引文献38

同被引文献64

引证文献9

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部